No Data
No Data
Shanxi C&Y Pharmaceutical Group (300254): The annual growth rate of smoking cessation drugs exceeds 170%, and rate optimization elevates profit margins.
Investment highlights: The company announced its performance for 2024 and Q1 of 2025: The company recently released its 2024 annual report and Q1 report for 2025, achieving a total operating revenue of 0.847 billion yuan in 2024, a year-on-year growth of 5.92%.
Qianyuan Pharmaceutical: Report for the first quarter of 2025
Qianyuan Pharmaceutical: 2024 Annual Report
Qianyuan Pharmaceutical: 2024 Annual Report Summary
Express News | Shanxi C&Y Pharmaceutical Group: The net income in 2024 is 42.1901 million yuan, a year-on-year increase of 67.45%.
Express News | Shanxi C&Y Pharmaceutical Group: The USA's tariff policy has a relatively small impact on the company.